“For Q3 2023, I am pleased by our strong preliminary financial results, including total revenue of $73.8M and Adjusted EBITDA of $2.0M, with these results beating the mid-point of our quarterly guidance on each metric. Additionally, we are grateful to be in a position to raise our full year 2023 revenue guidance range and reiterate our full year 2023 Adjusted EBITDA guidance range. We are also encouraged by our bookings results through Q3 2023, which are in line with our expectations,” said Dan Burton, CEO.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HCAT:
- Health Catalyst Reports Third Quarter 2023 Preliminary Results
- Health Catalyst to Announce Third Quarter 2023 Operating Results and Host Conference Call on Wednesday, November 8, 2023
- Health Catalyst price target lowered to $15 from $20 at BTIG
- Health Catalyst price target lowered to $10 from $14 at Evercore ISI
- Health Catalyst management to meet with BTIG